GSK AWP settlement
Executive Summary
GlaxoSmithKline settles average wholesale price class action litigation for $70 mil., the company announces Aug. 10. Plaintiffs alleged that GSK inflated certain AWPs - primarily for antiemetics Zofran and Kytril. The settlement, which covers all claims filed in Boston federal court, resolves most of the AWP litigation pending against GSK, company says. GSK reached civil settlements with six state attorneys general as part of a September settlement with the Department of Justice over Zofran and Kytril pricing (1"The Pink Sheet" Sept. 26, 2005, p. 6). Reportedly, there are more than a dozen remaining defendants involved in the AWP litigation, including AstraZeneca and Bristol-Myers Squibb...
You may also be interested in...
GSK’s AWP Pricing Settlement Includes Expanded Training Of Sales Reps
GlaxoSmithKline's $150 mil. settlement with the Department of Justice requires the company to expand its compliance training for its sales reps
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.